214 related articles for article (PubMed ID: 26950487)
1. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
Shi Y; Gao X; Hu Q; Li X; Xu J; Lu S; Liu Y; Xu C; Jiang D; Lin J; Xue A; Tan Y; Shen K; Hou Y
Lab Invest; 2016 Jun; 96(6):652-60. PubMed ID: 26950487
[TBL] [Abstract][Full Text] [Related]
2. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
[TBL] [Abstract][Full Text] [Related]
3. Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
Kou Y; Yang R; Wang Q
J Biosci; 2018 Dec; 43(5):1015-1023. PubMed ID: 30541960
[TBL] [Abstract][Full Text] [Related]
4. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression.
Qiu C; Feng YD; Yang X
Curr Med Sci; 2023 Oct; 43(5):935-946. PubMed ID: 37828372
[TBL] [Abstract][Full Text] [Related]
6. miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT.
Wang Y; Li J; Kuang D; Wang X; Zhu Y; Xu S; Chen Y; Cheng H; Zhao Q; Duan Y; Wang G
Cell Commun Signal; 2018 Apr; 16(1):16. PubMed ID: 29661252
[TBL] [Abstract][Full Text] [Related]
7. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
8. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.
Kim WK; Park M; Kim YK; Tae YK; Yang HK; Lee JM; Kim H
Clin Cancer Res; 2011 Dec; 17(24):7584-94. PubMed ID: 22042971
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
Mu J; Sun P; Ma Z; Sun P
J Cell Mol Med; 2020 Feb; 24(4):2519-2530. PubMed ID: 31957165
[TBL] [Abstract][Full Text] [Related]
11. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
12. Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib.
Zhang Z; Jiang NY; Guan RY; Zhu YK; Jiang FQ; Piao D
Neoplasma; 2018 Sep; 65(5):683-692. PubMed ID: 30249101
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of Metabolic Vulnerability in Imatinib -Resistant Gastrointestinal Stromal Tumor.
Huang WK; Gao J; Chen Z; Shi H; Yuan J; Cui HL; Yeh CN; Bränström R; Larsson C; Li S; Lui WO
Cells; 2020 May; 9(6):. PubMed ID: 32466502
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
[No Abstract] [Full Text] [Related]
15. The rs17084733 variant in the
Ravegnini G; Serrano C; Simeon V; Sammarini G; Nannini M; Roversi E; Urbini M; Ferrè F; Ricci R; Tarantino G; Pantaleo MA; Hrelia P; Angelini S
Epigenetics; 2019 Jun; 14(6):545-557. PubMed ID: 30983504
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.
Chen W; Li Z; Liu H; Jiang S; Wang G; Sun L; Li J; Wang X; Yu S; Huang J; Dong Y
Cell Death Dis; 2020 Mar; 11(3):198. PubMed ID: 32251287
[TBL] [Abstract][Full Text] [Related]
17. MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
Gao X; Shen K; Wang C; Ling J; Wang H; Fang Y; Shi Y; Hou Y; Qin J; Sun Y; Qin X
Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):72-5. PubMed ID: 24217767
[TBL] [Abstract][Full Text] [Related]
18. Chemokine receptor CCR6 expression is regulated by miR-518a-5p in colorectal cancer cells.
Rubie C; Kruse B; Frick VO; Kölsch K; Ghadjar P; Wagner M; Grässer F; Wagenpfeil S; Glanemann M
J Transl Med; 2014 Feb; 12():48. PubMed ID: 24559209
[TBL] [Abstract][Full Text] [Related]
19. microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.
Fan R; Zhong J; Zheng S; Wang Z; Xu Y; Li S; Zhou J; Yuan F
Clin Exp Med; 2015 May; 15(2):137-44. PubMed ID: 24706111
[TBL] [Abstract][Full Text] [Related]
20. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
Bauer S; Joensuu H
Drugs; 2015 Aug; 75(12):1323-34. PubMed ID: 26187774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
